Hikma Pharmaceuticals’ (HIK) “Overweight” Rating Reiterated at JPMorgan Chase & Co.
JPMorgan Chase & Co. restated their overweight rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a report released on Friday morning, Marketbeat.com reports. Separately, Berenberg Bank boosted their target price on Hikma Pharmaceuticals from GBX 2,400 ($31.02) to GBX 2,560 ($33.09) and gave the stock a “buy” rating in a report on […]
JPMorgan Chase & Co. restated their overweight rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a report released on Friday morning, Marketbeat.com reports. Separately, Berenberg Bank boosted their target price on Hikma Pharmaceuticals from GBX 2,400 ($31.02) to GBX 2,560 ($33.09) and gave the stock a “buy” rating in a report on […]
